Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Request metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended October 31, 2004 (Form 10-Q).
Stage: Development stage company focused on perfluorocarbon-based medical products, specifically "Oxycyte" (a blood substitute) and "Fluorovent" (an oxygen exchange fluid), as well as a glucose biosensor implant.
Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern due to an accumulated deficit of $22.0 million and reliance on future financing.
Key Financial Metrics
| Metric | Three Months Ended Oct 31, 2004 | Six Months Ended Oct 31, 2004 | Accumulated Deficit (Inception to Oct 31, 2004) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(599,956) | $(1,073,378) | $(22,023,311) |
| Net Loss Per Share | $(0.005) | $(0.009) | N/A |
| Cash and Equivalents | $110,141 (Ending Balance) | $110,141 (Ending Balance) | N/A |
| Working Capital | $(289,546) Deficit | $(289,546) Deficit | N/A |
| Current Assets | $130,841 | $130,841 | N/A |
| Current Liabilities | $420,387 | $420,387 | N/A |
| Cash Used in Operations | N/A | $(723,027) | $(16,144,983) Lifetime |
Material Changes vs. Prior Period
- Expenses: Total expenses for the six months ended Oct 31, 2004, increased by $148,969 compared to the prior year period.
- Research & Development: Increased from $498,710 to $529,081 (Six Months) due to continued focus on Oxycyte Phase II trial preparation.
- General & Administrative: Increased from $428,301 to $546,899 (Six Months), driven by a $33,000 increase in consulting fees (investor relations) and a $55,667 increase in management fees (amortization of deferred compensation).
- Liquidity: Cash and cash equivalents decreased from $302,310 at April 30, 2004, to $110,141 at October 31, 2004.
- Other Income: Decreased due to lower interest rates and reduced invested balances.
Guidance, Outlook, and Risks
- Product Development: Phase I clinical studies for Oxycyte were completed in December 2003 with results meeting expectations. The company is preparing for Phase II trials, expected to begin in calendar 2005. Phase II is estimated to cost approximately $2 million and take one year.
- Capital Needs: The company has difficulty raising capital. Management estimates that recent funding (discussed below) plus existing cash will fund operations for at least 12 months. Continued development beyond 2005 depends on securing outside resources.
- Subsequent Financing (Post-Period):
- December 2004: Received $1,800,000 for 9,000,000 shares and warrants.
- December 2004: Received $87,500 for 437,500 shares and warrants.
- Unpaid Subscription: A $2.35 million subscription agreement from May 2004 remains unpaid; the company is not relying on these funds.
- Risks: Substantial doubt about going concern status; reliance on FDA approval for products; potential dilution from future equity issuances; and the need for significant additional funding for Phase II and Phase III trials.
Investor Verification Checklist
- Capital Runway: Verify the actual receipt and utilization of the $1.8875 million raised in December 2004 to confirm the 12-month liquidity runway claim.
- Unpaid Subscription: Confirm the status of the $2.35 million unpaid subscription agreement from May 2004 and whether it has been cancelled or restructured.
- Phase II Timeline: Monitor the initiation of Phase II clinical trials for Oxycyte, as delays could accelerate the need for additional capital.
- Related Party Transactions: Review ongoing payments to the specialty contract manufacturer (where an officer is a minority shareholder) for Oxycyte production.
- Dilution: Assess the impact of the significant number of warrants issued in December 2004 and the potential exercise of the 2004 stock purchase agreement.